Navigation Links
HotStarTaq PCR Handbook

Primer length pmol/g 20 pmol
18mer
20mer
25mer
30mer 168
152
121
101 119 ng
132 ng
165 ng
198 ng
Use 0.10.5 M of each primer in PCR. For most applications, a primer concentration of 0.2 M will be sufficient. Storage: Lyophilized primers should be dissolved in a small volume of distilled water or TE to make a concentrated stock solution. Prepare small aliquots of working solutions containing 10 pmol/l to avoid repeated thawing and freezing. Store all primer solutions at 20C. Primer quality can be checked on a denaturing polyacrylamide gel; a single band should be seen. Degenerate PCR primers

Occasionally, the exact nucleotide sequence of the target-template DNA will not be known, for instance when it has been deduced from an amino acid sequence. To enable such templates to be amplified by PCR, degenerate
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Related biology technology :

1. HotStarTaq DNA Polymerase
2. QIAGEN Multiplex PCR Handbook
3. TransMessenger Transfection Reagent Handbook
4. Transfection Reagent Selector Kit Handbook
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: HotStarTaq PCR Handbook

Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 1ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 3Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 1Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 2Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 11Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 12Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 13Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 14Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 15Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 16Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 17